Siemens officials question whether they should keep the company’s majority stake in its former medtech division, Siemens Healthineers (XETRA: SHL.DE).
The plan is to evaluate the economic opportunities for Siemens in the healthcare space and then determine how instrumental it is to have Healthineers as an investment, Siemens CFO Ralf Thomas told the Handelsblatt newspaper in Germany in an article published today. He expected the deliberations to wrap up by a capital market day at the end of 2025.
Siemens presently owns a more than 75% stake in Siemens Healthineers, which spun off from its parent in 2017. Handelsblatt said the percentage could drop to 70% after Siemens completes its planned $10.6 billion acquisition of U.S. software company Altair.
SHL.DE shares were down nearly 2% to €51.20 apiece by the close of trading today in Frankfurt.
Erlangen, Germany–based Siemens Healthineers is the third largest medical device company in the world, according to our most recent annual Medtech Big 10o report. Its revenue grew just over 3%, to €22.4 billion, during its most recent fiscal year ended Sept. 30. The company’s total headcount grew to 72,000.
Siemens Healthineers CEO Bernd Montag said in November: “We achieved our targets for the fiscal year with a very good fourth quarter despite the current market weakness in China. This underlines the fundamental strength of our company and the contribution of the entire Healthineers team. We will carry this momentum into the 2025 financial year.”
